Proteomic Biomarker Predicts Therapeutical Effects of Oxaliplatin Combining with Fluoropyrimidine Metastatic Gastric Cancer Patients by the SELDI-Proteinchip Platform

摘要

Background/Aims: To evaluate potential protein markers for oxaliplatin-based first-line chemotherapy of metastatic gastric cancer (MGC), we have used proteomic analysis to compare the difference of serum proteomic spectra between responsive and non-responsive MGC patients. Methodology: Serum samples were collected before chemotherapy. Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF-MS) protein chip array technology was applied to compare the differences of serous protein spectra between the twenty responsive patients and another fourteen non-responsive patients. Cross validation was applied to identify the proper markers for an accurate judgment of prognosis. Results: Fifty proteins were picked out for significantly increased or decreased expression (p<0.05, Student t-test). Among them, sixteen protein masses with 1081, 1267, 2941, 2985, 3148, 3165, 3199, 3219, 3249, 3281, 4182, 4390, 4482, 4509, 4533 and 5001 m/z were chosen as components of the best proteomic biomarker pattern for judgment of chemotherapy prognosis in MGC patients, achieving a sensitivity of 95% (19/20) and a specificity of 78.6% (11/14), respectively. Conclusions: SELDI-TOF-MS screens out the specific protein markers that help oncologists with judging the prognosis of oxaliplatin in combination with fluoropyrimidine, thus orientating first-line palliative chemotherapy for MGC patients.